Your browser is no longer supported. Please, upgrade your browser.
Rocket Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.51 Insider Own1.50% Shs Outstand56.29M Perf Week-4.52%
Market Cap2.68B Forward P/E- EPS next Y-2.88 Insider Trans33.57% Shs Float55.35M Perf Month2.15%
Income-139.70M PEG- EPS next Q-0.69 Inst Own100.00% Short Float14.84% Perf Quarter-31.79%
Sales- P/S- EPS this Y-60.00% Inst Trans-1.17% Short Ratio17.02 Perf Half Y38.95%
Book/sh8.94 P/B4.90 EPS next Y-5.90% ROA-33.80% Target Price72.90 Perf Year161.31%
Cash/sh7.88 P/C5.55 EPS next 5Y10.80% ROE-43.10% 52W Range16.53 - 67.48 Perf YTD-20.19%
Dividend- P/FCF- EPS past 5Y29.90% ROI- 52W High-35.14% Beta1.86
Dividend %- Quick Ratio14.90 Sales past 5Y- Gross Margin- 52W Low164.79% ATR2.44
Employees91 Current Ratio14.90 Sales Q/Q- Oper. Margin- RSI (14)45.51 Volatility5.09% 5.62%
OptionableYes Debt/Eq0.12 EPS Q/Q-179.20% Profit Margin- Rel Volume0.35 Prev Close43.19
ShortableYes LT Debt/Eq0.11 Earnings- Payout- Avg Volume482.78K Price43.77
Recom1.60 SMA20-0.02% SMA50-8.50% SMA2009.01% Volume170,875 Change1.34%
Mar-02-21Initiated Stifel Buy $64
Feb-18-21Initiated Needham Buy $75
Dec-16-20Initiated UBS Buy $75
Dec-08-20Downgrade Oppenheimer Outperform → Perform
Jul-02-20Initiated JP Morgan Overweight
Jun-25-20Resumed BofA/Merrill Buy $34
Jun-01-20Resumed Oppenheimer Outperform
Nov-06-19Initiated Chardan Capital Markets Buy $30
Sep-26-19Initiated Piper Jaffray Overweight
Apr-23-19Initiated Robert W. Baird Outperform
Mar-15-19Initiated BofA/Merrill Buy $27
Feb-05-19Initiated Oppenheimer Outperform $39
Sep-13-18Initiated Ladenburg Thalmann Buy $30
Jul-10-18Initiated William Blair Outperform
Apr-27-21 04:30PM  
Apr-14-21 07:00AM  
Apr-12-21 04:50PM  
Mar-29-21 07:00AM  
Mar-22-21 07:00AM  
Mar-10-21 09:56AM  
Mar-09-21 07:00AM  
Feb-25-21 07:00AM  
Feb-18-21 10:02AM  
Jan-15-21 08:30PM  
Jan-11-21 07:00AM  
Jan-06-21 07:00AM  
Dec-18-20 12:10AM  
Dec-14-20 04:01PM  
Dec-10-20 10:52AM  
Dec-09-20 11:32PM  
Dec-08-20 04:00PM  
Dec-07-20 02:30PM  
Dec-06-20 10:00AM  
Dec-02-20 07:00AM  
Nov-24-20 07:00AM  
Nov-13-20 07:00AM  
Nov-04-20 10:37AM  
Oct-16-20 07:15AM  
Oct-13-20 12:04PM  
Oct-01-20 07:00AM  
Sep-24-20 07:00AM  
Sep-04-20 07:00AM  
Sep-02-20 07:00AM  
Aug-27-20 07:00AM  
Aug-26-20 07:00AM  
Aug-05-20 07:00AM  
Jul-13-20 07:00AM  
Jul-08-20 12:53PM  
Jun-29-20 07:00AM  
Jun-27-20 03:16PM  
Jun-08-20 07:00AM  
May-26-20 07:00AM  
May-12-20 07:00AM  
May-10-20 10:39PM  
May-06-20 07:00AM  
May-05-20 07:00AM  
Apr-22-20 07:00AM  
Apr-09-20 08:22AM  
Apr-02-20 09:00AM  
Mar-27-20 10:04AM  
Mar-19-20 07:00AM  
Mar-05-20 07:00AM  
Feb-24-20 07:00AM  
Feb-18-20 07:00AM  
Feb-11-20 09:15AM  
Feb-06-20 07:00AM  
Jan-09-20 09:44AM  
Jan-06-20 12:00PM  
Dec-29-19 03:24AM  
Dec-16-19 07:00AM  
Dec-13-19 04:01PM  
Dec-11-19 07:21AM  
Dec-10-19 10:45PM  
Dec-09-19 07:00AM  
Dec-08-19 06:00PM  
Dec-06-19 07:00AM  
Dec-05-19 07:00AM  
Dec-04-19 09:27AM  
Nov-27-19 07:00AM  
Nov-07-19 07:00AM  
Nov-06-19 09:00AM  
Nov-05-19 07:00AM  
Nov-01-19 11:16AM  
Oct-24-19 07:00AM  
Oct-22-19 07:00AM  
Oct-15-19 07:00AM  
Oct-01-19 07:00AM  
Sep-23-19 07:00AM  
Sep-10-19 07:00AM  
Sep-04-19 07:00AM  
Aug-28-19 07:00AM  
Aug-22-19 07:00AM  
Aug-07-19 07:00AM  
Jul-31-19 07:00AM  
Jun-25-19 09:24PM  
Jun-18-19 07:00AM  
May-29-19 10:00AM  
May-23-19 03:00PM  
May-09-19 01:54PM  
May-08-19 07:13AM  
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has four clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energeticas, Medioambientales y Tecnologicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO Inc. The company also has a research and collaboration agreement with Lund University; and strategic collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shah GauravCEOMar 31Option Exercise1.6975,880128,237612,751Apr 01 09:08 PM
Patel KinnariChief Operating OfficerMar 24Option Exercise1.4093,962131,979188,939Mar 26 06:17 PM
Schwartz Jonathan DavidChief Medical OfficerFeb 01Option Exercise1.23224,529277,166224,529Feb 03 09:06 PM
Patel KinnariChief Operating OfficerDec 28Sale56.7216,761950,74594,977Dec 30 04:50 PM
RTW INVESTMENTS, LPDirectorDec 10Buy56.00247,72013,872,32017,530,044Dec 14 07:19 PM